Humabiologics has launched a research-grade human collagen product designed to support scientists facing significant funding challenges in the life sciences sector. The new biomaterial offers researchers an ethically sourced, high-quality alternative to traditional research materials at a price point that addresses budget constraints currently impacting scientific research.
The company's new collagen product, part of its HumaDerm family, is sourced from FDA-registered and AATB-accredited tissue banks using tissues that are not suitable for transplantation. This approach provides researchers with a clinically relevant material for regenerative medicine, drug testing, tissue models, and organ-on-a-chip applications.
According to Mohammad Albanna, Founder and CEO of Humabiologics, the product directly responds to the growing financial challenges facing scientific research. Federal budget cuts to the National Institutes of Health (NIH) and National Science Foundation (NSF) grants have created significant obstacles for researchers seeking to advance their work.
Tim Bertram from the National Science Foundation Piedmont Triad Regenerative Medicine Engine highlighted the significance of this innovation, noting that the new collagen eliminates cost barriers that have historically forced researchers to compromise on the physiological relevance of their research materials.
The launch builds on Humabiologics' recent grant from the Piedmont Triad Regenerative Medicine Engine and represents a strategic collaboration with institutions like the Wake Forest Institute for Regenerative Medicine. By offering human biomaterials at a price point lower than animal alternatives, the company aims to accelerate the translation of scientific research into clinical solutions.
This development is particularly crucial at a time when scientific research faces increasing financial pressures. By providing an affordable, high-quality human-derived biomaterial, Humabiologics offers researchers a pathway to maintain the momentum of their work without sacrificing the quality and relevance of their research models.
